A study registered under ClinicalTrials.gov ID NCT01763931 investigated the pharmacodynamics of IG-HIF1 in breast cancer, revealing insights into HIF1α’s role in predicting tamoxifen resistance (97). Here, HIF1A is linked to breast carcinoma.